401 related articles for article (PubMed ID: 10089889)
21. Breast cancer biology blossoms in the clinic.
Nass SJ; Hahm HA; Davidson NE
Nat Med; 1998 Jul; 4(7):761-2. PubMed ID: 9662357
[No Abstract] [Full Text] [Related]
22. Chemoprevention of breast cancer.
O'Shaughnessy JA
JAMA; 1996 May; 275(17):1349-53. PubMed ID: 8614122
[No Abstract] [Full Text] [Related]
23. [Effectiveness of adjuvant therapy for patients with early-stage (I-IIa) breast cancer].
Semiglazov VF
Vopr Onkol; 1998; 44(2):137-41. PubMed ID: 9615814
[No Abstract] [Full Text] [Related]
24. Tamoxifen in early breast cancer.
Benson JR
Lancet; 1998 Aug; 352(9125):404-5. PubMed ID: 9717955
[No Abstract] [Full Text] [Related]
25. Ovarian suppression for early breast cancer.
Wilcken N; Stockler M
Lancet; 2007 May; 369(9574):1668-70. PubMed ID: 17512837
[No Abstract] [Full Text] [Related]
26. STAR: first-year recruitment efforts set brisk pace for future.
CA Cancer J Clin; 2000; 50(5):271-2. PubMed ID: 11075236
[No Abstract] [Full Text] [Related]
27. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.
Tjalma WA
Lancet; 2003 Oct; 362(9390):1156-7. PubMed ID: 14550711
[No Abstract] [Full Text] [Related]
28. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
Munster PN; Horton J
Cancer Control; 2001; 8(6):478-9. PubMed ID: 11807416
[No Abstract] [Full Text] [Related]
29. Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
Ziegler J
J Natl Cancer Inst; 1996 Aug; 88(16):1100-2. PubMed ID: 8757185
[No Abstract] [Full Text] [Related]
30. Adjuvant trials of toremifene vs tamoxifen: the European experience.
Holli K
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):23-7. PubMed ID: 9556787
[TBL] [Abstract][Full Text] [Related]
31. Ductal carcinoma-in-situ.
Wickerham DL
J Clin Oncol; 2001 Sep; 19(18 Suppl):98S-100S. PubMed ID: 11560982
[No Abstract] [Full Text] [Related]
32. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.
Baroni G; Pedotti A; Orecchia R
Lancet; 2003 Oct; 362(9390):1155; author reply 1155-6. PubMed ID: 14550709
[No Abstract] [Full Text] [Related]
33. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
34. [Sequencing of adjuvant treatment after surgery for invasive breast cancer].
Petit T; Claude L; Carrie C
Cancer Radiother; 2004 Feb; 8(1):54-8. PubMed ID: 15093202
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen, raloxifene, and the prevention of breast cancer.
Jordan VC; Morrow M
Endocr Rev; 1999 Jun; 20(3):253-78. PubMed ID: 10368771
[No Abstract] [Full Text] [Related]
36. [Current status of treatment for early-stage invasive breast cancer].
Kásler M; Polgár C; Fodor J
Orv Hetil; 2009 May; 150(22):1013-21. PubMed ID: 19465349
[TBL] [Abstract][Full Text] [Related]
37. Segmental mastectomy and tamoxifen alone provide adequate locoregional control of breast cancer in elderly women.
Yeh S; Tan LR; O'Connell TX
Am Surg; 1997 Oct; 63(10):854-7. PubMed ID: 9322656
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer (non-metastatic).
Dixon JM; Rodger A; Stebbing J
Clin Evid; 2005 Jun; (13):2226-57. PubMed ID: 16135326
[No Abstract] [Full Text] [Related]
39. Breast cancer hopes.
Zurlinden J
Nurs Spectr (Wash D C); 1998 Jun; 8(11):17-8. PubMed ID: 10542741
[No Abstract] [Full Text] [Related]
40. Designer estrogens: breast cancer benefit, remaining questions.
Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
